97 related articles for article (PubMed ID: 6288064)
1. Cyclic GMP in urine to monitor the response to ovarian cancer to therapy.
Turner GA; Ellis RD; Guthrie D; Latner AL; Ross WM; Skillen AW
Br J Obstet Gynaecol; 1982 Sep; 89(9):760-4. PubMed ID: 6288064
[TBL] [Abstract][Full Text] [Related]
2. Monitoring ovarian cancer using urine cyclic GMP. A two-centre study.
Turner GA; Greggi S; Guthrie D; Benedetti Panici P; Ellis RD; Scambia G; Mancuso S
Eur J Gynaecol Oncol; 1990; 11(6):421-7. PubMed ID: 1964900
[TBL] [Abstract][Full Text] [Related]
3. The treatment of advanced cystadenocarcinoma of the ovary with gestronol and continuous oral cyclophosphamide.
Guthrie D
Br J Obstet Gynaecol; 1979 Jul; 86(7):497-500. PubMed ID: 476014
[TBL] [Abstract][Full Text] [Related]
4. Urine cyclic nucleotide concentrations in cancer and other conditions; cyclic GMP: a potential marker for cancer treatment.
Turner GA; Ellis RD; Guthrie D; Latner AL; Monaghan JM; Ross WM; Skillen AW; Wilson RG
J Clin Pathol; 1982 Aug; 35(8):800-6. PubMed ID: 6286732
[TBL] [Abstract][Full Text] [Related]
5. Random urinary cyclic 3',5' guanosine monophosphate in epithelial ovarian cancer: relation to other prognostic variables and to survival.
Luesley DM; Blackledge GR; Chan KK; Newton JR
Br J Obstet Gynaecol; 1986 Apr; 93(4):380-5. PubMed ID: 3008807
[TBL] [Abstract][Full Text] [Related]
6. Serial urinary cyclic guanosine monophosphate measurements in the assessment of response to treatment in epithelial ovarian cancer.
Luesley DM; Chan KK; Newton JR; Blackledge GR
Br J Obstet Gynaecol; 1987 May; 94(5):461-6. PubMed ID: 3034324
[TBL] [Abstract][Full Text] [Related]
7. [The effect of various factors on the results of chemotherapy in patients with recurrent ovarian serous cystadenocarcinoma].
Dzhilavian GA; Vinokurov VL
Vopr Onkol; 1984; 30(3):16-21. PubMed ID: 6424327
[TBL] [Abstract][Full Text] [Related]
8. The use of cytotoxic chemotherapy in conjunction with gynaecological surgery.
Guthrie D
Clin Obstet Gynaecol; 1978 Dec; 5(3):709-27. PubMed ID: 367674
[No Abstract] [Full Text] [Related]
9. [Selective intra-arterial administration of cis-diamminedichloroplatinum (CDDP) to metastatic tumors of ovarian cancer].
Tateyama I; Kamitani N; Tominaga T; Shibata T; Yamashita K; Hamanaka D; Ishii Y
Nihon Gan Chiryo Gakkai Shi; 1984 Dec; 19(10):2296-304. PubMed ID: 6543448
[No Abstract] [Full Text] [Related]
10. Urinary excretion of cyclic guanosine 3':5'-monophosphate and cyclic adenosine 3':5'-monophosphate in rats bearing transplantable liver and kidney tumors.
Criss WE; Murad F
Cancer Res; 1976 May; 36(5):1714-6. PubMed ID: 178429
[TBL] [Abstract][Full Text] [Related]
11. Urinary cyclic GMP after treatment of gynecological cancer. A prognostic marker of clinical outcome.
Orbo A; Hanevik M; Jaeger R; Van Heusden S; Sager G
Anticancer Res; 2007; 27(4C):2591-6. PubMed ID: 17695420
[TBL] [Abstract][Full Text] [Related]
12. Subrenal capsule assay as a predictor of clinical response of ovarian cancer to chemotherapy: Part II.
Mäenpää J
Obstet Gynecol; 1985 Nov; 66(5):714-8. PubMed ID: 3903584
[TBL] [Abstract][Full Text] [Related]
13. [A randomized clinical trial of cyclophosphamide versus adriamycin, cyclophosphamide, 5-fluorouracil and methotrexate in advanced ovarian carcinoma--a preliminary report ].
Chylak V; Ilijas M; Krusić J; Kolarić K
Lijec Vjesn; 1982; 104(3-4):120-2. PubMed ID: 6750298
[No Abstract] [Full Text] [Related]
14. Urinary cyclic AMP and cyclic GMP in normal and asthmatic subjects during exercise.
Linklater HA; Strickland KP; Cunningham DA; Griffiths JC; Trevithick JR
Med Sci Sports; 1979; 11(3):250-5. PubMed ID: 230405
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide and floxuridine adjuvant chemotherapy for stage III and IV carcinoma of the ovary.
VillaSanta U
Gynecol Oncol; 1980 Aug; 10(1):44-50. PubMed ID: 6447099
[No Abstract] [Full Text] [Related]
16. [Polymer-drug complexes in the treatment of extensive ovarian cancer].
Novikova EG; Borisov VI; Dmitriev DG; Zel'vin BM; Karseladze AI; Shchitkov KG; Li AD
Sov Med; 1991; (11):27-9. PubMed ID: 1767307
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin/cyclophosphamide combination chemotherapy for advanced ovarian cancer.
Teeling M; Hayes Y; Fitzmaurice B; McGing P; Carney DN
Semin Oncol; 1992 Feb; 19(1 Suppl 2):102-6. PubMed ID: 1411620
[TBL] [Abstract][Full Text] [Related]
18. Levels of adenosine 3',5' cyclic monophosphate and guanosine 3',5' cyclic monophosphate in single urine specimens collected from a large population of healthy subjects.
Turner GA; Ellis RD; Guthrie D; Latner AL; Skillen AW; Ross WM
Ann Clin Biochem; 1982 Mar; 19(Pt 2):77-82. PubMed ID: 6280576
[TBL] [Abstract][Full Text] [Related]
19. Urinary cyclic GMP excretion and blood pressure levels in a general population.
Cui R; Iso H; Pi J; Kumagai Y; Yamagishi K; Tanigawa T; Shimojo N; Shimamoto T
Atherosclerosis; 2004 Jan; 172(1):161-6. PubMed ID: 14709371
[TBL] [Abstract][Full Text] [Related]
20. Fucosylated forms of alpha-1-antitrypsin that predict unresponsiveness to chemotherapy in ovarian cancer.
Thompson S; Guthrie D; Turner GA
Br J Cancer; 1988 Nov; 58(5):589-93. PubMed ID: 3265332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
